News

When a massive tree toppled in the floodplains of Fonte Boa, a region in the Brazilian Amazon, local fishermen noticed ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...
Uranus, the mysterious ice giant at the edge of our solar system, has fascinated scientists for generations.Explore the ...
Records, court filings and emails reveal how federal review of Enbridge's Great Lakes tunnel project leaves tribal officials ...
Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...
Considering it’s been two years since the anime’s finale, it’s fascinating how Attack on Titan fans still continue to dissect ...
Woolly mammoths have become the poster child for de-extinction. The giant land mammals have long held our intrigue and ...
Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that ...
A submerged river valley under the Madura Strait was found packed with Homo erectus fossils and other bones submerged since ...
A groundbreaking study of 7,000-year-old exposed coral reef fossils reveals how human fishing has transformed Caribbean reef ...
Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.